
Grifols, S.A. GRFS
$ 9.29
0.05%
Annual report 2024
added 02-14-2026
Grifols, S.A. Operating Cycle 2011-2026 | GRFS
Annual Operating Cycle Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 0.000171 | 261 | 263 | 275 | 282 | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 282 | 0.000171 | 216 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amarin Corporation plc
AMRN
|
157 | $ 14.81 | -0.34 % | $ 6.04 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
53.8 | $ 3.24 | 13.85 % | $ 182 M | ||
|
Aptorum Group Limited
APM
|
4.89 | $ 0.79 | -7.27 % | $ 4.31 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Biogen
BIIB
|
402 | $ 195.63 | 0.06 % | $ 28.7 B | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Bristol-Myers Squibb Company
BMY
|
153 | $ 60.51 | 1.12 % | $ 123 B | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Amneal Pharmaceuticals
AMRX
|
123 | $ 14.8 | 1.13 % | $ 4.57 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |